Company: RGBP
Filing Date: 2025-05-16
Form Type: 10-Q
Source: 0001641172-25-011206
Chunk: 19

Company: Regen BioPharma Inc
Filing Date: 2025-05-16
Form: 10-Q
Item: Part I, Item 1
Chunk 19
---
 Inc. (“ Regen”) entered into an agreement (“ Agreement”)
whereby:

1) Zander shall return for cancellation194,285,714shares of the Series A Preferred stock of Regen (“ Conversion Shares”) acquired by Zander through conversion of $340,000of
principal indebtedness of a $350,000convertible note payable issued by Regen to Zander. Subsequent to this event the principal amount
due to Zander by Regen pursuant to the Convertible Note shall be $350,000which shall be applied pursuant to the Agreement.

2) A $35,000one time charge due to Zander by Regen
(“ One Time Charge”) shall be applied pursuant to the Agreement.

3) $75,900of principal indebtedness due to Regen
by Zander and $4,328of accrued but unpaid interest due by Regen to Zander shall be applied pursuant to the Agreement.

No actions were taken by any of the parties to enforce
the terms of the Agreement.

On April 15, 2021 the Agreement was amended as follows
so that the material terms and conditions shall be:

a) Zander shall not return the
Conversion shares for cancellation and the principal indebtedness of the aforementioned convertible note shall not reflect such
return

b) As of December 16, 2019 all
principal and accrued interest payable by Regen to Zander on that date resulting from Promissory Notes issued by Regen to Zander
shall be credited towards amounts due by Zander pursuant to that agreement, as amended, entered into by and between Zander and Regen
on June 23, 2015 (“ License Agreement”) whereby Regen granted to Zander an exclusive worldwide right and license for the
development and commercialization of certain intellectual property controlled by Regen for non-human veterinary therapeutic use for
a term of fifteen years and that License Assignment And Consent agreement entered into by and between Regen, KCL and Zander on
December 17, 2018 whereby Regen transferred and assigned to KCL all rights, duties, and obligations of Regen under the License
Agreement and KCL agreed to assume such duties and obligations thereunder and be bound to the terms of the License Agreement with
respect thereto.

Zander and Regen are under common control.

On January 13, 2022 Regen Biopharma, Inc. entered
into a sublease agreement with BST Partners (“ BST”) whereby Regen Biopharma